Cerevel Therapeutics Holdings, Inc. (CERE)

NASDAQ: CERE · IEX Real-Time Price · USD

41.90

-0.09 (-0.21%)

At close: Apr 24, 2024, 4:00 PM

41.80

-0.10 (-0.24%)

Pre-market: Apr 25, 2024, 8:41 AM EDT

CERE Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	112.62	87.59	58.24	45.81	33.17
Research & Development	334.64	280.26	161.86	103.3	50.29
Operating Expenses	447.27	367.85	220.1	149.12	83.46
Operating Income	-447.27	-367.85	-220.1	-149.12	-83.46
Interest Expense / Income	10.57	3.92	0	-0.22	0
Other Expense / Income	-25.49	-20.42	5.24	3.27	44.88
Pretax Income	-432.34	-351.35	-225.33	-152.17	-128.34
Income Tax	0.5	0.16	0	-0.02	0.05
Net Income	-432.84	-351.51	-225.33	-152.14	-128.39
Preferred Dividends	0	0	0	-3.87	0
Net Income Common	-432.84	-351.51	-225.33	-148.27	-128.39
Shares Outstanding (Basic)	162	151	137	74	44
Shares Outstanding (Diluted)	162	151	137	74	44
Shares Change	7.13%	10.76%	85.46%	66.58%	-
EPS (Basic)	-2.67	-2.32	-1.65	-2.01	-2.90
EPS (Diluted)	-2.67	-2.32	-1.65	-2.01	-2.90
Free Cash Flow	-346.11	-297.14	-189.05	-136.69	-71.82
Free Cash Flow Per Share	-2.14	-1.96	-1.38	-1.86	-1.63
EBITDA	-416.15	-342.53	-222.6	-151.99	-128.17
Depreciation & Amortization	5.63	4.9	2.73	0.4	0.18
EBIT	-421.77	-347.43	-225.33	-152.39	-128.34

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).